Debanjali Mitra

Direct economic burden of chronic hepatitis C virus in a United States managed care population.

Goals and Background To estimate all-cause and disease-related resource utilization and costs among managed care enrollees with chronic hepatitis C virus (HCV). Study A large United States claims database was analyzed (1/1/2002 to 12/31/2006). Inclusion criteria were: diagnosis of chronic HCV; no hepatitis B diagnoses; ≥6 and ≥12 months of continuous plan enrollment prediagnosis and postdiagnosis, respectively. Use and costs of medical services and prescription drugs over a 12-month period postdiagnosis were evaluated. Outcomes were assessed in controls without HCV matched (1:1) on age, sex, and plan enrollment. All cost estimates were generated using multivariate generalized linear models to adjust for additional covariates and skewness common in health care cost data. Results Of the 20,662 patients who met all inclusion criteria, mean age was 49 years; 61% were male. Adjusted all-cause costs were

Cost and Cost-effectiveness of the COMBINE Study in Alcohol-Dependent Patients

20,961 per HCV patient, compared with

Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns

5451 per control (P<0.0001). Hospitalization occurred in 24% of HCV patients compared with 7% of controls (P<0.0001). Mean inpatient costs were

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

5892 and

Direct Economic Burden of High-Risk and Metastatic Melanoma in the Elderly: Evidence from the SEER-Medicare Linked Database

1159 per patient, respectively (P<0.0001). Patients with HCV had higher prescription costs compared with controls (

The effect of screening and brief intervention for risky drinking on health care utilization in managed care organizations.

6191 vs.

Reply to L. Reale et al. “More and better should be done to guarantee evidence-based management of ADHD in children across Europe”

1315; P<0.0001). At

PCN94 PREDICTORS OF TREATMENT CHOICE IN HIGH RISK AND METASTATIC MELANOMA: EVIDENCE FROM LINKED ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE CLAIMS DATA

6864 per patient, disease-related costs were nearly one-third of all costs in patients with HCV, which exceeded all-cause costs among controls by 26% (P<0.0001). Conclusions Chronic HCV is a costly disease to managed care organizations. Disease-related costs in HCV exceed all-cause costs in demographically matched controls. Increased efforts in HCV screening and early treatment, particularly before progression to liver cirrhosis, may lead to long-term cost savings in HCV management for managed care systems.

PCN96 REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA: EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE

CONTEXTnThe COMBINE (Combined Pharmacotherapies and Behavioral Intervention) clinical trial recently evaluated the efficacy of medications, behavioral therapies, and their combinations for the outpatient treatment of alcohol dependence. The costs and cost-effectiveness of these combinations are unknown and of interest to clinicians and policy makers.nnnOBJECTIVEnTo evaluate the costs and cost-effectiveness of the COMBINE Study interventions after 16 weeks of treatment.nnnDESIGNnA prospective cost and cost-effectiveness study of a randomized controlled clinical trial.nnnSETTINGnEleven US clinical sites.nnnPARTICIPANTSnOne thousand three hundred eighty-three patients having a diagnosis of primary alcohol dependence.nnnINTERVENTIONSnThe study included 9 treatment groups; 4 groups received medical management for 16 weeks with naltrexone, 100 mg/d, acamprosate, 3 g/d, or both, and/or placebo; 4 groups received the same therapy as mentioned earlier with combined behavioral intervention; and 1 group received combined behavioral intervention only.nnnMAIN OUTCOMES MEASURESnIncremental cost per percentage point increase in percentage of days abstinent, incremental cost per patient of avoiding heavy drinking, and incremental cost per patient of achieving a good clinical outcome.nnnRESULTSnOn the basis of the mean values of cost and effectiveness, 3 interventions are cost-effective options relative to the other interventions for all 3 outcomes: medical management (MM) with placebo (

PIN34 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CHRONIC HEPATITIS C IN A MANAGED CARE POPULATION

409 per patient), MM plus naltrexone therapy (